A new meta-analysis of 3.9 million pregnancies offers important guidance for pregnant women managing asthma. The research identified three critical findings: first, evidence linking beta-2-adrenergic agonists to autism spectrum disorder remains inconsistent across studies; second, the extreme selectivity required to identify reliable evidence (only 8 of 16,824 studies qualified) reflects the complexity of pregnancy research; and third, the documented risks of uncontrolled asthma during pregnancy likely exceed potential developmental concerns from medication use.
For clinical practice, this means pregnant women with asthma should not delay or discontinue treatment based on preliminary concerns. Instead, expectant mothers should engage in detailed conversations with their obstetricians and pulmonologists to develop personalized treatment plans that prioritize maternal respiratory health and fetal well-being. Continued asthma control remains essential for preventing serious pregnancy complications.
Was this article helpful?
